Silk Road Medical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chas McKhann

Chief executive officer

US$13.4m

Total compensation

CEO salary percentage	0.8%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3.8yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chas McKhann's remuneration changed compared to Silk Road Medical's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$13m	US$106k	-US$56m

Compensation vs Market: Chas's total compensation ($USD13.42M) is above average for companies of similar size in the German market ($USD1.30M).

Compensation vs Earnings: Insufficient data to compare Chas's compensation with company performance.

CEO

Chas McKhann (54 yo)

less than a year

Tenure

US$13,423,834

Compensation

Mr. Charles S. McKhann, also known as Chas, serves as Chief Executive Officer at Silk Road Medical, Inc since November 02, 2023 and serves as Director since 2023. He serves as President, Chief Executive Of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles McKhann	CEO & Director	less than a year	US$13.42m	no data
Lucas Buchanan	CFO & COO	7.8yrs	US$6.62m	0.40% $ 3.1m
Kevin Klemz	EVP, Chief Legal Officer & Secretary	1.8yrs	US$3.64m	0.015% $ 121.9k
Andrew Davis	Chief Commercial Officer	3.8yrs	US$4.87m	0.17% $ 1.4m
Richard Ruedy	Executive Vice President of Clinical	9.8yrs	US$1.97m	0.30% $ 2.4m
Mhairi Jones	Chief Accounting Officer & VP of Finance	6.3yrs	no data	0.19% $ 1.6m
Tammy Leitsinger	Compliance Officer & VP of Medical Affairs	2.3yrs	no data	no data
Jorge O'Hara	Vice President of Marketing	less than a year	no data	no data
Alison Highlander	Vice President of Human Resources	no data	no data	no data
Sumaira MacDonald	Executive Medical Director	5.2yrs	no data	no data
Lynn Lewis	Investors Relations Officer	no data	no data	no data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 2OW's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Charles McKhann	CEO & Director	1.3yrs	US$13.42m	no data
Jack Lasersohn	Independent Chairman	17.1yrs	US$263.49k	0.016% $ 124.7k
Elizabeth Weatherman	Independent Director	11.1yrs	US$212.49k	0.37% $ 2.9m
Donald Zurbay	Independent Director	6.2yrs	US$228.14k	0.0052% $ 41.5k
Rick Anderson	Independent Director	3.6yrs	US$221.31k	0.0036% $ 28.5k
Tony Chou	Independent Director	17.2yrs	US$202.47k	0.19% $ 1.5m
Tanisha Carino	Independent Director	2.8yrs	US$207.47k	0.0021% $ 17.0k
Kevin Ballinger	Independent Director	3.4yrs	US$220.47k	0.033% $ 264.4k

4.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2OW's board of directors are considered experienced (4.9 years average tenure).

Silk Road Medical Management

Management criteria checks 2/4

Key information

Recent management updates

Silk Road Medical, Inc, Annual General Meeting, Jun 18, 2024

CFO & COO recently sold €156k worth of stock

Insufficient new directors

Silk Road Medical Announces Chief Executive Officer Changes

Erica J. Rogers to Retire as Chief Executive Officer of Silk Road Medical, Inc

Chief Commercial Officer recently sold €133k worth of stock

Recent updates

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.43 loss in 1Q 2023)

Silk Road Medical, Inc, Annual General Meeting, Jun 18, 2024

Silk Road Medical, Inc to Report Q1, 2024 Results on Apr 30, 2024

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus

CFO & COO recently sold €156k worth of stock

Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.44 loss per share (vs US$1.54 loss in FY 2022)

Silk Road Medical, Inc to Report Q4, 2023 Results on Feb 28, 2024

Insufficient new directors

New minor risk - Shareholder dilution

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.29 loss in 3Q 2022)

Silk Road Medical Announces Chief Executive Officer Changes

Silk Road Medical, Inc to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Erica J. Rogers to Retire as Chief Executive Officer of Silk Road Medical, Inc

Chief Commercial Officer recently sold €133k worth of stock

Second quarter 2023 earnings released: US$0.35 loss per share (vs US$0.44 loss in 2Q 2022)

New major risk - Share price stability

Silk Road Medical, Inc to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: US$0.43 loss per share (vs US$0.48 loss in 1Q 2022)

Silk Road Medical, Inc Provides Revenue Guidance for the Year 2023

President recently sold €802k worth of stock

Full year 2022 earnings released: US$1.54 loss per share (vs US$1.44 loss in FY 2021)

Silk Road Medical, Inc to Report Q4, 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.40 loss in 3Q 2021)

Silk Road Medical, Inc Provides Earnings Guidance for the Full Year 2022

Silk Road Medical, Inc to Report Q3, 2022 Results on Nov 08, 2022

Silk Road Medical, Inc has completed a Follow-on Equity Offering in the amount of $100.000026 million.

Silk Road Medical, Inc Provides Earnings Guidance for the Quarter Ended September 30, 2022

Silk Road Medical, Inc. Announces First Patient Enrolled in ROADSTER 3 Post Approval Study Evaluating TCAR® System in Treatment of Standard Surgical Risk Patients

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.30 loss in 2Q 2021)

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2022

Silk Road Medical, Inc to Report Q2, 2022 Results on Jul 26, 2022

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

Silk Road Medical Announces Expanded Medicare Coverage for TCAR in Standard Surgical Risk Patients

First quarter 2022 earnings released: US$0.48 loss per share (vs US$0.31 loss in 1Q 2021)

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2022

Silk Road Medical Announces FDA Approval of Expanded Indications for the Enroute Transcarotid Stent System

No longer forecast to breakeven

Silk Road Medical, Inc to Report Q1, 2022 Results on May 04, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Silk Road Medical, Inc Provides Financial Guidance for the Full Year 2022

Silk Road Medical, Inc to Report Q4, 2021 Results on Feb 24, 2022

President recently bought €92k worth of stock

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.31 loss in 3Q 2020)

Forecast to breakeven in 2023

Silk Road Medical, Inc Announce First Ever Analysis of TCAR in Standard Surgical Risk Patients Demonstrates Clinical Benefits in Large Comparative Dataset

Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2020)

Independent Chairman recently sold €204k worth of stock

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.32 loss in 1Q 2020)

Silk Road Medical, Inc Raises Earnings Guidance for the Full Year 2021

Full year 2020 earnings released: US$1.44 loss per share (vs US$2.28 loss in FY 2019)

Revenue misses expectations

Silk Road Medical, Inc Announces Positive Results from a Comparative-Effectiveness Study

Silk Road Medical, Inc to Report Q4, 2020 Results on Mar 01, 2021

New 90-day low: €45.00

Silk Road Medical, Inc. Announces Changes to Board of Directors

New 90-day low: €46.60

Third quarter 2020 earnings released: US$0.31 loss per share

Revenue beats expectations

Third quarter 2020 earnings released: US$0.31 loss per share

Revenue beats expectations

Silk Road Medical, Inc Appoints Rick Anderson as a Member of the Board

Silk Road Medical, Inc Announces Executive Appointments

Silk Road Medical, Inc. Provides No Annual Guidance for 2020